Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $4.02
Previous CloseN/A
Volume775.41K
Average Volume (3M)875.08K
Market Cap
$20.38M
Enterprise Value$29.81M
Total Cash (Recent Filing)$80.63M
Total Debt (Recent Filing)$1.92M
Price to Earnings (P/E)―
Beta3.84
Next Earnings
Mar 27, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding58,024,730
10 Day Avg. Volume496,050
30 Day Avg. Volume875,082
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.54
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.29
Enterprise Value/Ebitda-0.35
Forecast
1Y Price Target
$5.00Price Target Upside1328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
BioAtla News
PremiumCompany Announcements
BioAtla Awards Executive Bonuses and Stock Units
PremiumCompany Announcements
BioAtla Secures $9.2M for Clinical Program Advancements
PremiumCompany Announcements
BioAtla Highlights Advancements in CAB Cancer Therapy
---
Bulls Say, Bears Say
Bulls Say
Regulatory SupportThe FDA has shown support for a pivotal trial in HNSCC for BioAtla's ozuriftamab vedotin, which could potentially lead to accelerated approval.
Bears Say
Financial PerformanceBioAtla's financial results for 3Q24 reported a net loss, with R&D expenses exceeding estimates.
Pipeline ChallengesThe development of mecbotamab vedotin (BA3011) for both undifferentiated pleomorphic sarcoma and non-small cell lung cancer indications has stalled.
---
Ownership Overview
9.23% Insiders
4.85% Mutual Funds
25.32% Other Institutional Investors
55.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.24 and its highest was $4.02 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $20.38M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Mar 27, 2025 which is in 2 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.413 by $0.193.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -0.39.
How many shares outstanding does BioAtla have?
BioAtla has 58,024,730 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.413. Following the earnings report the stock price went down -5.405%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
---
BioAtla Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (1328.57% Upside)
$5.00 (1328.57% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.43%
12-Months-Change
Fundamentals
Return on Equity
-139.06%
Trailing 12-Months
Asset Growth
-58.88%
Trailing 12-Months
Company Description
BioAtla
BioAtla, Inc. (BCAB) is a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibodies. These are novel protein therapeutics that are designed to be more effective and safer than traditional antibodies by being active only in the tumor microenvironment. BioAtla operates primarily in the healthcare sector, specifically targeting cancer treatment with its proprietary technologies.
---
BCAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates significant progress in clinical trials and strategic collaborations, with promising results in key oncology programs and financial improvements. However, there are challenges in maintaining R&D spending and managing cash reserves.Read More>---
BCAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(1328.57% Upside)
Technical Analysis
Best Analysts Covering BCAB
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-41.19%
reiterated a buy rating 10 months ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -41.19% per trade.
---